×

Clinical stage

UMN Pharma Inc.

http://www.umnpharma.com

UMN Pharma Inc. is a pharmaceutical company dedicated to developing innovative pharmaceutical products that will satisfy unmet medical needs; our most important mission is to provide good candidates having proof of concept in clinical stage to big Pharma. Our core competencies reside in utilizing our significant experience in the pharmaceutical industry to generate time-efficient, focused development plans followed by rapid preclinical and clinical development to meet international regulatory specifications. We have a pipeline of diverse novel small molecule and protein drug candidates targeting large (cancer and diabetes) and relatively small (pancreatitis and muscular dystrophy) pharmaceutical markets that are seriously underserved by existing therapeutics, and influenza vaccine: 1) UMN-01, an anti-cancer drug, is a first-in-class GRP78 down-regulator specifically under the condition of glucose starvation, which is well seen in various solid tumors. We are currently conducting the preclinical studies, and the clinical study will be started in late 2007.

  • 12/8/2013
  • 14
  • 0

American BioHealth Group LLC

http://www.thehearingpill.com

American BioHealth Group LLC, is a clinical stage pharmaceutical company located in San Diego, California. Our target market is individuals wishing to help prevent acute hearing loss or tinnitus (ringing in the ears), those seeking aids in treatment immediately after acute hearing loss or tinnitus and those experiencing balance disorders. American BioHealth Group has developed a two-part therapeutic approach.

  • 12/8/2013
  • 11
  • 0

Royalmount Pharma Inc

http://www.royalmountpharma.com

Royalmount Pharma is an emerging clinical stage pharmaceutical company focused on developing and commercializing innovative and affordable medicines to address underserved demand in various pharmaceutical markets. The company improves the formulation and delivery of pharmaceutical products, extends their use into non-exploited therapeutic indications and develops novel combination therapies. The goal is to clinically enhance pharmaceutical products and as such generate novel intellectual property.

  • 12/8/2013
  • 11
  • 0

ACCESS Oncology , Inc.

http://www.accessoncology.com

ACCESS Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and marketing novel therapeutics for cancer and related conditions. ACCESS has built a portfolio of proprietary anti-cancer product candidates through the in-licensing and acquiring of clinical-stage product candidates from emerging biotechnology companies.

  • 12/8/2013
  • 14
  • 0

Acucela Inc.

http://www.acucela.com

Acucela Inc. is a clinical stage biotech company discovering new drug therapies for eye diseases. Neurodegenerative retinal diseases such as macular degeneration, Stargardt's disease, retinitis pigmentosa and glaucoma, significantly affect quality of life for over 50 million people worldwide, and there is a drastic lack of therapies available. Until now, ophthalmic drug discovery technologies have been very limited. Acucela uses proprietary OcuScreenTM disease-specific assays and other technologies to identify and discover compounds that have safety and efficacy in treating these diseases. These technologies represent a tremendous breakthrough in ophthalmic drug discovery. Acucela Inc. has two divisions: The Drug Discovery Division serves to discover and develop drug compounds to treat retinal eye diseases. ACU-3223 is currently in a Phase I clinical trial. The OcuScreenTM Division provides services to pharmaceutical companies and other customers, using Acucela's proprietary technologies to generate data on custom drug compounds. Three papers have been published on OcuScreen assays (see the "news" section for more details).

  • 12/8/2013
  • 11
  • 0

Humanetics Corporation

http://www.humaneticscorp.com

Humanetics Corporation is a clinical-stage pharmaceutical company engaged in accelerated discovery, development and commercialization of proprietary drugs in markets with urgent and unmet needs. With a focus on non-synthetic, orally-administered, bioactive compounds for disease prevention and treatment, Humanetics has an extensive patent portfolio and an active pipeline of compounds that range from discovery phase to human clinical trials. Currently, Humanetics is focused on three biotherapeutic areas with urgent and unmet needs: immunodeficiency disorders, neurodegenerative diseases and metabolic dysfunction.

  • 12/8/2013
  • 13
  • 0

Zelos Therapeutics Inc.

http://www.zelostherapeutics.com

Zelos Therapeutics specializes in the development of innovative treatments for bone disorders and related indications in large, underserved markets. Led by an experienced team of biopharmaceutical executives and funded by leading health care investors, Zelos is advancing a portfolio of product opportunities into late stage clinical trials. We are pursuing programs linked by the common mechanism of stimulating bone formation to provide therapeutic benefit in the following key indications:

  • 12/8/2013
  • 10
  • 0

ImmunoVaccine Technologies Inc.

http://www.immunovaccine.com

ImmunoVaccine Technologies is a local biotechnology company located in downtown Halifax. We operate in a high-growth, fast-paced industry where innovation is the key to success. We are currently recruiting an Administrative Assistant who will be an assistant to the Office Manager. The ideal candidate will be motivated, enthusiastic, personable, team-oriented, have previous office experience and excellent communication and inter-personal skills. Exceptional computer skills and proficiency in all applications of Microsoft Office are required. In keeping with our corporate policies we are seeking an individual who, like our technology, is innovative and will complement our team in all aspects of our company. If you have the desire to excel within our dynamic organization, please forward your resume to: Angela Thorne ImmunoVaccine Technologies Inc. 1819 Granville Street, Suite 303, Halifax, NS B3J 3R1 email: at.ivt@immunovaccine.com We thank all applicants for their responses, but only those selected for interviews will be contacted.

  • 12/8/2013
  • 11
  • 0

OncoGenex Technologies Inc.

http://www.oncogenex.ca

OncoGenex is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. Encouraging preliminary data from four of the Phase 2 studies has been reported in 2007. OGX 427 has begun evaluation in Phase 1 clinical studies, while our third product candidate, OGX-225, has completed preclinical pharmacology studies.

  • 12/8/2013
  • 14
  • 0

Urigen Pharmaceuticals , Inc.

http://www.urigen.com

Urigen Pharmaceuticals, Inc. is engaged in the designing and implementation of products for patients with urological ailments, including the development of products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, and Overactive Bladder (OAB). The Company conducts its business through its wholly owned subsidiary Urigen N.A. Urigen N.A. is a specialty pharmaceutical company engaged in the development and commercialization of therapeutic products for urological disorders. The URG101 project targets painful bladder syndrome, which affects approximately 10.5 million men and women in North America. The clinical-stage projects, URG301 and URG302, target acute urgency in patients diagnosed with an overactive bladder. (Source: 10-K)

  • 12/8/2013
  • 12
  • 0

Cardiokine , Inc.

http://www.cardiokine.com

CardioKine Inc. is a specialty pharmaceutical company focused on the development of pharmaceuticals for the treatment and prevention of heart failure and related cardiovascular indications. We both in-license and develop innovative new compounds and therapies to address what is a growing epidemic around the industrialized world. In the U.S. alone there are five million heart failure patients with over one million hospitalizations and 550,000 new cases each year. It is estimated that heart failure accounts for three billion dollars in pharmaceutical costs and $30 billion in total healthcare costs annually. Cardiokine raised $37MM in March 2004 in a Series A private equity financing led by Perseus-Soros Biopharmaceutical Fund, L.P. and HealthCare Ventures VII, L.P. Also participating in the financing were Care Capital Investments II, L.P., CIBC WMC Inc., and Burrill Life Sciences Capital Fund, L.P. An additional $50MM was raised in April 2006 in a Series B private equity round led by Advent Venture Partners and Fidelity Biosciences Group. Also participating in the second round were Teachers Private Capital, Perseus-Soros Biopharmaceutical Fund, Health Ventures VII, LP, Care Capital Investments II, LP, CIBC World Markets, Inc. and Burrill Life Sciences Capital Fund.

  • 12/8/2013
  • 15
  • 0

GlycoDesign Inc.

http://www.glycodesign.com

GlycoDesign is a drug discovery and development company focused on developing proprietary drugs for the treatment or prevention of cardiovascular and chronic inflammatory diseases, as well as cancer. The Company's resources are focused on two lead antithrombotic drug candidates, GH9001 and ATH, completing Phase I and preclinical development respectively, as well as the development of novel glycotherapeutics targeted at the treatment of chronic inflammation and cancer, which are at the discovery stage.

  • 12/8/2013
  • 10
  • 0

Acuity Pharmaceuticals

http://www.acuitypharma.com

Founded in late 2002, Acuity Pharmaceuticals is a product-focused pharmaceutical firm that is a pioneer in commercializing small interfering RNA (siRNA) therapeutics. Acuity is developing treatments for serious diseases of the eye and retina -- age-related wet macular degeneration (wet AMD) and diabetic retinopathy (DR). Current therapies for these conditions are limited, and they represent the number one and two causes of irreversible vision loss in the developed world. The number of patients afflicted with AMD and DR is growing rapidly as a result of aging populations and the increasing incidence of diabetes worldwide. The easily accessed and enclosed nature of the eye makes ocular diseases ideal targets for siRNA-based therapies. In preclinical studies, Acuity's siRNA compounds have demonstrated efficacy in shutting down production of vascular endothelial growth factor (VEGF), a naturally-occurring protein that is central to development of wet AMD and DR and is also implicated in other diseases. Acuity's core siRNA technology is licensed from the University of Pennsylvania, and was developed by leading retinal researchers at the Scheie Eye Institute.

  • 12/8/2013
  • 15
  • 0

AlphaRx Inc.

http://www.alpharx.com

AlphaRx is developing several drug products in the therapeutic categories of Osteoarthritis and Infectious Disease. AlphaRx intends to file IND and NDA submissions with the FDA (when necessary) and license these products to other pharmaceutical companies for worldwide commercialization. The following is a list of AlphaRx's Pharmaceutical Products in the pipeline: Name Indication Delivery Route Stage Indaflex Ô Osteoarthritis Topical Phase II Streptomycin NDS Ô Tuberculosis Oral Preclinical Zysolin Ô Infection Parenteral Preclinical

  • 12/8/2013
  • 11
  • 0

Cytochroma Inc.

http://www.cytochroma.com

Cytochroma Inc. is a development stage specialty pharmaceutical company focused on the treatment and prevention of disorders related to Vitamin D insufficiency. The Company has a portfolio of therapeutics with lower development risk for the indications of Vitamin D insufficiency and for secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). Cytochroma's pipeline products address significant unmet medical needs with a target market that is expected to grow significantly, reaching more than $1.2 billion annually by 2010 in North America alone. Cytochroma's understanding of the biology of Vitamin D combined with our management's experience in the development and commercialization of Vitamin D therapies, uniquely positions us to positively impact the outcomes of CKD patients suffering from diseases related to Vitamin D insufficiency.

  • 12/8/2013
  • 15
  • 0

Topigen Pharmaceuticals Inc.

http://www.topigen.com

TOPIGEN is developing several new classes of drugs and is actively progressing two drug candidates in Phase II trials for COPD and asthma. These drugs are uniquely focused on inhibiting multiple inflammation targets underlying the chronic pulmonary diseases. TOPIGEN also has a number of discovery research programs focused on the identification of novel compounds for the treatment of COPD and allergic rhinitis. By applying its knowledge and expertise in respiratory care, along with its proprietary mRNA-based chemistry, TOPIGEN is seeking to make a positive difference for patients.

  • 12/8/2013
  • 13
  • 0

MethylGene Inc.

http://www.methylgene.com

MethylGene Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for cancer. As of December 31, 2007, the Company is running multiple Phase I, Phase I/II, and Phase II clinical trials with its compound MGCD0103, an HDAC oncology inhibitor. As of December 31, 2007, the Company is also progressing a number of other preclinical programs including MGCD290 its HDAC antifungal clinical candidate. On August 20, 2007, the Company entered into research collaboration with Pharmion for the development of small molecule inhibitors targeting sirtuins, a separate and distinct class of HDAC enzymes. (Source: ARS)

  • 12/8/2013
  • 10
  • 0

Note

Not found any data